Form 4: Moderna Director Noubar Afeyan Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 1, 2024, Noubar Afeyan, a director of Moderna, sold shares of the company's common stock.
- The sales were executed under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
- A total of 14,990 shares were sold in multiple transactions at varying weighted average prices ranging from $109.07 to $113.48.
- Following the reported transactions, Afeyan directly owns 2,026,931 shares of Moderna common stock.
- Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.
- He disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports a transaction under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.
Industry Context
Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on inside information. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices.
Comparison to Industry Standards
- Comparing insider sales to industry standards requires analyzing the volume and frequency of sales relative to the company's market capitalization and the insider's holdings.
- It's also important to consider the reasons for the sale, such as diversification or personal financial needs.
- Without further context, it's difficult to determine if these sales are unusual compared to peers like Pfizer or BioNTech.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in stock price.
- However, since the sale was conducted under a pre-arranged trading plan, the impact is likely to be minimal.
Key Dates
| Date | Description |
|---|---|
| 2023-02-27 | Date of adoption of Rule 10b5-1 trading plan |
| 2023-11-07 | Date of amendment of Rule 10b5-1 trading plan |
| 2024-05-01 | Date of share sale transactions |
| 2024-05-03 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.